Abstract
Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Current Drug Therapy
Title: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review
Volume: 6 Issue: 4
Author(s): Rajashree Hirlekar, Harshal Garse and Vilasrao Kadam
Affiliation:
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Abstract: Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Export Options
About this article
Cite this article as:
Hirlekar Rajashree, Garse Harshal and Kadam Vilasrao, Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review, Current Drug Therapy 2011; 6 (4) . https://dx.doi.org/10.2174/157488511798109637
DOI https://dx.doi.org/10.2174/157488511798109637 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a ‘New Frontier’?
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial Activity of Phenolics and Glucosinolate Hydrolysis Products and their Synergy with Streptomycin against Pathogenic Bacteria
Medicinal Chemistry The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms : A Collaboration Update
Current Genomics ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Current Gene Therapy Foamy Virus Vectors: An Awaited Alternative to Gammaretro- and Lentiviral Vectors
Current Gene Therapy Tubulin-based Structure-affinity Relationships for Antimitotic Vinca Alkaloids
Anti-Cancer Agents in Medicinal Chemistry Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets Transcription, DNA Damage and Beyond: The Roles of Histone Ubiquitination and Deubiquitination
Current Protein & Peptide Science Environmental Contaminants Perturb Fragile Protein Assemblies and Inhibit Normal Protein Function
Current Chemical Biology Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia
Current Pharmacogenomics Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science